CKD Staging and Management
| CKD Stage | eGFR | Key Actions |
|---|---|---|
| G1 | ≥90 (+ kidney damage markers) | Treat cause; BP <130/80; annual monitoring |
| G2 | 60–89 | Same; lifestyle; address CVD risk |
| G3a | 45–59 | Nephrology if rapid decline; anaemia screen; bone disease screen |
| G3b | 30–44 | Nephrology referral; avoid nephrotoxic drugs; prepare patient for RRT discussion |
| G4 | 15–29 | Pre-dialysis planning; vascular access creation; transplant referral |
| G5 | <15 | Dialysis or kidney transplant; conservative care if chosen |
What causes kidney disease?
The two most common causes of CKD worldwide are diabetes (diabetic nephropathy) and high blood pressure (hypertensive nephropathy). Together, they account for about 60–70% of all CKD cases. Other causes include:
- Glomerulonephritis: inflammation of the kidney filtering units
- Polycystic kidney disease (genetic)
- Repeated urinary tract infections
- Kidney stones causing obstruction
- Long-term use of NSAIDs (ibuprofen, naproxen) or certain antibiotics
- Lupus and other autoimmune conditions
Symptoms of kidney disease
CKD is often called a "silent disease" because early stages have no symptoms. Later stages cause:
- Swelling in the feet, ankles and legs (fluid retention)
- Puffy face, especially around the eyes in the morning
- Fatigue and weakness (anaemia from low EPO production)
- Decreased urine output or foamy urine (proteinuria)
- Itchy skin (uraemic pruritis)
- Nausea, loss of appetite, metallic taste in the mouth
- Shortness of breath (fluid in lungs)
- High blood pressure that's difficult to control
Why eGFR Alone Is Half the Picture
Staging kidney disease by eGFR is so familiar that people assume it is the whole assessment. It is not, and the reason is one of the largest pieces of evidence in kidney medicine.
A collaborative meta-analysis pooled data on 105,872 people with albumin-to-creatinine ratio measured and over 1.1 million with urine dipstick results. It found that eGFR and albuminuria predict mortality independently of one another, and that their effects multiply rather than overlap.2 Two people with identical eGFR can carry very different risk depending on how much albumin is leaking into their urine.
Two findings are worth stating plainly. Risk was flat across eGFR between about 75 and 105, then climbed as eGFR fell below that — so a mildly reduced number is not automatically alarming. And albuminuria rose with risk without any threshold: there was no level below which it stopped mattering.2 Compared with a very low ratio, all-cause mortality was around 20% higher at 1.1 mg/mmol and roughly doubled at 33.9.2
It is also why treatment decisions do not follow from eGFR alone. Albuminuria is what several kidney-protective drugs are chosen to reduce, and a falling ACR is evidence that treatment is doing its job even when eGFR moves very little.
What Slows CKD Progression?
| Intervention | Effect | Drug/Target |
|---|---|---|
| BP control | Most important modifiable factor | Target <130/80; ACEi or ARB for proteinuric CKD |
| SGLT2 inhibitors | ~40% reduction in CKD progression + mortality | Empagliflozin, dapagliflozin: now first-line for CKD |
| Protein restriction | Mild benefit in advanced CKD | <0.8 g/kg/day — dietitian-guided |
| Avoidance of NSAIDs | NSAIDs reduce renal blood flow: avoid | Especially in CKD G3–5 |
| Smoking cessation | Reduces CKD progression and CVD risk | Essential |
ICD-10-CM diagnosis codes
CKD is coded by stage, which is based on eGFR:
| ICD-10-CM code | Description |
|---|---|
| N18.1 | Chronic kidney disease, stage 1 |
| N18.2 | Chronic kidney disease, stage 2 (mild) |
| N18.30 | Chronic kidney disease, stage 3 unspecified |
| N18.4 | Chronic kidney disease, stage 4 (severe) |
| N18.5 | Chronic kidney disease, stage 5 |
| N18.6 | End stage renal disease |
Codes shown are from the current ICD-10-CM classification (FY2026) and are provided for general reference. Clinical coding is performed by trained coders using the full medical record.
References
The clinical information on this page is based on peer-reviewed sources indexed in PubMed, the biomedical literature database of the US National Library of Medicine.
- Grams ME, Coresh J, Matsushita K, et al.. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. JAMA. 2023;330(13):1266-1277. doi:10.1001/jama.2023.17002 · PMID 37787795
- Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81. PMID 20483451 · doi:10.1016/S0140-6736(10)60674-5
Related reading
- Kidney Disease (CKD)What is kidney disease? Learn about CKD stages, early warning signs…
- Kidney Function Test (KFT / RFT)What does your KFT kidney function test mean? Understand creatinine…
- Creatinine TestWhat does your creatinine blood test mean? Understand normal creatinine…
- Hypertension: Understanding and Managing High Blood PressuHypertension affects 1 in 4 adults and is the leading cause of stroke…
- Diabetes: Understanding Your Blood Sugar TestsUnderstanding diabetes blood tests: HbA1c, fasting blood sugar…
- Liver Disease: From Fatty Liver to CirrhosisLiver disease ranges from fatty liver (NAFLD) to cirrhosis and liver…